Biotech Startups
9,603 companies tagged Biotech, with their investors and founders.
DiogenX is a preclinical-stage biotech company developing biologic therapeutics aimed at restoring insulin-producing beta cells for people with Type 1 diabetes. It focuses on new treatment options for diabetic patients as an alternative to lifelong exogenous insulin.
3 investors
Dispersa manufactures biosurfactants derived entirely from food waste, offering a platform of biodegradable bioproducts such as its flagship PuraSurf M ingredient for home, industrial, and institutional (HI&I) formulations. It sells to formulators, brands, and manufacturers seeking sustainable replacements for synthetic surfactants.
3 investors
DP Technology develops AI for Science tools and intelligent systems for scientific discovery, including its Uni-Fold/ๅฎ็ฅ science discovery engine, computation and simulation software (Hermite, Piloteye), and the Bohrium research platform. It serves scientists and R&D organizations in fields such as life sciences and materials science.
3 investors
3 investors
Dyne Therapeutics develops targeted therapies for genetically driven neuromuscular diseases using its proprietary FORCE platform. The company focuses on discovery, clinical development, and commercialization of treatments for rare genetic disorders.
3 investors
Earnest develops microbial seed coatings and agricultural biology products derived from prairie ecosystems to improve soil health and crop performance for farmers. The company has expanded from soil amendments to seed coatings that deliver biology directly on seeds, with plans to scale planter box treatments.
3 investors
EBT Medical develops neuromodulation technologies targeting the Saphenous nerve to treat pelvic health disorders, particularly overactive bladder. The clinical-stage company, spun out of the University of Toronto, is advancing paradigm-shifting medical devices for patients with pelvic health conditions.
3 investors
Ecovative grows whole-cut meat alternatives and other materials from mycelium using its AirMycelium indoor cultivation platform, which integrates with existing mushroom farming infrastructure. Its products include MyBacon, a sliceable vegan bacon sold in over 3,000 US stores, and Forager, a leather-like material in development with fashion and electronics brands.
3 investors
EdiGene is a biotechnology company developing genome-editing-based therapies, including allogeneic cell therapies and in vivo RNA base editing platforms, alongside a high-throughput genome editing screening platform. It focuses on treatments for genetic diseases and cancer.
3 investors
Electra Therapeutics develops antibody therapeutics targeting Signal Regulatory Protein (SIRP) for immunological diseases and cancer treatment. The company explores and validates novel drug targets with a focus on breakthrough therapies addressing underlying disease pathology.
3 investors
Electrochaea is a Power-to-Gas technology company whose patented biomethanation process uses a proprietary strain of archaea to convert CO2 and green hydrogen into grid-quality renewable e-methane. It licenses its technology to energy and industrial companies to produce low-carbon methane for gas grids and renewable fuel across multiple sectors.
3 investors
Elemental Machines provides an IoT platform combining hardware, software, and data science to monitor lab and manufacturing equipment, environments, and workflows in real time. It serves R&D, manufacturing, academia, and government science operations with continuous monitoring, contextual alerts, and GxP/GMP/GLP compliance support.
3 investors
Elixir Therapeutics develops therapies for rare diseases and aging-related conditions using proprietary technologies, including ZSCAN4 for telomere extension in stem cell therapies and Bobcat mRNA for delivering large genes. The company is advancing clinical candidates for telomere biology disorders and Duchenne muscular dystrophy.
3 investors
Elkedonia is developing a novel antidepressant aimed at patients who do not respond to current depression treatments, using a precision medicine approach. It focuses on mental health disorders and antidepressant therapy.
3 investors
Endomedix is developing PLEXimine, a technology platform based on polysaccharide chemistry that lets surgeons form structured medical devices in situ during procedures. The company focuses on biosurgery and related medical applications.
3 investors
Endpoint Health develops immunology-focused therapeutics paired with diagnostic tests designed to match individual patients with treatments suited to their biology for critical and chronic illnesses.
3 investors
EnduraTx develops small-molecule medicines that form permanent covalent bonds with disease-causing RNA to block production of proteins that cannot be drugged at the protein level, targeting conditions such as certain cancers and neurodegenerative diseases. Its TRANSCEND platform uses next-generation sequencing to map drug-RNA interactions at single-nucleotide resolution across many RNA targets simultaneously.
3 investors
Enedra analyzes tumor evolution patterns by decoding convergent genomic signatures from cancer genomic data. The company uses its CASPAROV platform to identify conserved genetic patterns across tumor populations and cancer models.
3 investors
EnginZyme develops a patented enzyme immobilisation technology to create stable, bespoke biocatalysts for use in multi-step enzymatic reactions. The company targets chemical and manufacturing companies seeking cleaner, less energy-intensive biomanufacturing processes.
3 investors
Enifer produces PEKILOยฎ, a fermentation-derived fungal mycoprotein used as a drop-in protein ingredient for aquafeed, pet food, and human food production. The Finnish biotech company markets the ingredient as a sustainable, high-protein alternative to soy and animal protein for food industry manufacturers.
3 investors
EnsiliTech develops ensilication technology, a silica-based method to stabilise vaccines and biopharmaceuticals so they can be stored and transported without refrigeration. The company serves the pharmaceutical and biotech industry and originated from research at the University of Bath.
3 investors
Entac Medical develops wearable devices that apply predictive analytics and AI to biological acoustic signals to predict patient adverse events, aiming to improve patient outcomes and reduce hospital readmissions and cost of care. It serves the healthcare sector as a digital health company.
3 investors
Enthera Srl is a privately held pharmaceutical company founded in 2016 and based in Milan, Italy.
3 investors
Entrada Therapeutics is a biotech company developing intracellular therapeutics based on its proprietary EEV Platform, aimed at reaching previously inaccessible or undruggable disease-causing targets inside cells. Its pipeline spans discovery to clinical-stage treatments for retinal, neuromuscular, and metabolic diseases, including Duchenne muscular dystrophy.
3 investors